Efficacy and Safety of Treatments for REM Sleep Behaviour Disorder in Parkinson's Disease: a Systematic Review and Bayesian Network Meta-analysis Protocol

Overview

Journal BMJ Open

Specialty General Medicine

Date 2021 Dec 18

PMID 34921073

Authors

Fabin Lin

Yanhong Weng

Xiaofeng Lin

Dihang Wu

Yixiao Su

Guoen Cai

Affiliations

Soon will be listed here.

Abstract

Introduction: Sleep disorders are the main non-motor characteristics of Parkinson's disease (PD). The quality of life is significantly impacted by rapid eye movement sleep behaviour disorder (RBD). It is not clearly evidenced in the literature that some medications can reduce the dream activities of patients with PD and RBD and improve sleep quality. And, they have side effects that may increase the severity of this disease. To further understand which medication has better efficacy and fewer adverse effects for patients with PD and RBD, it is necessary to perform a network meta-analysis.

Methods And Analysis: This protocol is performed accordingly to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols and the Cochrane Collaboration Handbook.A thorough literature selection will be conducted up to September 2021 using PubMed, Cochrane Library (The Cochrane Database of Systematic Reviews) and Embase. We will not only include randomised controlled trials, but prospective, retrospective cohort, case-control, nested case-control, case-cohort, cross-sectional and case series. We will use the Cochrane Collaboration tool to assess the risk of bias. Pairwise and network meta-analyses will be conducted using the R netmeta package and Stata V.14.0. The relative ranking probability of the best intervention will be estimated using the surface under the cumulative ranking curve. Additionally, sensitivity analysis, subgroup analysis, quality assessment and publication bias analysis will be performed.

Ethics And Dissemination: No research ethics approval is required for this systematic review, as no confidential patient data will be used. We will disseminate our findings through publication in a peer-reviewed journal and conference presentations, and our review will support development of a BMJ Rapid Recommendations providing contextualised clinical guidance based on this body of evidence.

Prospero Registration Number: CRD42020206958.

References

Albin R, Koeppe R, Chervin R, Consens F, Wernette K, Frey K . Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology. 2000; 55(9):1410-2. DOI: 10.1212/wnl.55.9.1410. View

Aurora R, Zak R, Maganti R, Auerbach S, Casey K, Chowdhuri S . Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010; 6(1):85-95. PMC: 2823283. View

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. DOI: 10.1136/bmj.g7647. View

Iranzo A, Molinuevo J, Santamaria J, Serradell M, Marti M, Valldeoriola F . Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006; 5(7):572-7. DOI: 10.1016/S1474-4422(06)70476-8. View

McGrane I, Leung J, St Louis E, Boeve B . Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2014; 16(1):19-26. PMC: 4306603. DOI: 10.1016/j.sleep.2014.09.011. View

Gagnon J, Postuma R, Mazza S, Doyon J, Montplaisir J . Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 2006; 5(5):424-32. DOI: 10.1016/S1474-4422(06)70441-0. View

Jansen J, Crawford B, Bergman G, Stam W . Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008; 11(5):956-64. DOI: 10.1111/j.1524-4733.2008.00347.x. View

Iranzo A, Lomena F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M . Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol. 2010; 9(11):1070-7. DOI: 10.1016/S1474-4422(10)70216-7. View

Dias S, Welton N, Caldwell D, Ades A . Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010; 29(7-8):932-44. DOI: 10.1002/sim.3767. View

10.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

11.

Tan S, Wan Y . Pramipexole in the treatment of REM sleep behaviour disorder: A critical review. Psychiatry Res. 2016; 243:365-72. DOI: 10.1016/j.psychres.2016.06.055. View

12.

St Louis E, Boeve A, Boeve B . REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies. Mov Disord. 2017; 32(5):645-658. DOI: 10.1002/mds.27018. View

13.

Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S . Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005; 48(2):301-10. DOI: 10.1016/j.neuropharm.2004.09.007. View

14.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

15.

Sasai T, Inoue Y, Matsuura M . Effectiveness of pramipexole, a dopamine agonist, on rapid eye movement sleep behavior disorder. Tohoku J Exp Med. 2012; 226(3):177-81. DOI: 10.1620/tjem.226.177. View

16.

Li S, Lam S, Zhang J, Yu M, Chan J, Liu Y . A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 2016; 21:114-20. DOI: 10.1016/j.sleep.2015.12.020. View

17.

Videnovic A, Ju Y, Arnulf I, Cochen-De Cock V, Hogl B, Kunz D . Clinical trials in REM sleep behavioural disorder: challenges and opportunities. J Neurol Neurosurg Psychiatry. 2020; 91(7):740-749. PMC: 7735522. DOI: 10.1136/jnnp-2020-322875. View

18.

Boeve B, Silber M, Ferman T, Lucas J, Parisi J . Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001; 16(4):622-30. DOI: 10.1002/mds.1120. View

19.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

20.

McCarter S, Boswell C, St Louis E, Dueffert L, Slocumb N, Boeve B . Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013; 14(3):237-42. PMC: 3617579. DOI: 10.1016/j.sleep.2012.09.018. View